Anatomical classification of advanced biliary tract cancer predicts programmed cell death protein 1 blockade efficacy.

ABSTRACT:

Background

Immune checkpoint blockade (ICB)-based immunotherapy has inspired new hope for advanced biliary tract cancer (BTC) treatment; however, there are no prior studies that primarily focus on different anatomical types of unresectable BTCs reacting differently to ICB.

Methods

We retrospectively collected data on advanced BTC patients who received anti-programmed cell death protein 1 (anti-PD1) therapy from two affiliated hospitals of Sun Yat-Sen university. The effects of anti-PD1 were compared for different anatomical sites. The GSE32225 and GSE132305 datasets were used to further analyze differences in the immune microenvironments between intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC).

Results

A total of 198 advanced BTC patient

SUBMITTER: Huang L 

PROVIDER: S-EPMC11392842 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature